TME Pharma is selling at 0.15 as of the 23rd of November 2024; that is 7.14% up since the beginning of the trading day. The stock's last reported lowest price was 0.14. TME Pharma has hardly any chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for TME Pharma NV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Although TME Pharma's alpha and beta are two of the key measurements used to evaluate TME Pharma's performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TME Pharma stock to make a market-neutral strategy. Peer analysis of TME Pharma could also be used in its relative valuation, which is a method of valuing TME Pharma by comparing valuation metrics with similar companies.
When running TME Pharma's price analysis, check to measure TME Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TME Pharma is operating at the current time. Most of TME Pharma's value examination focuses on studying past and present price action to predict the probability of TME Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TME Pharma's price. Additionally, you may evaluate how the addition of TME Pharma to your portfolios can decrease your overall portfolio volatility.